



## A proposal to consider: sensitivity, specificity and normal range values of the enzymatic deficiency of lysosomal enzymes

### Author names and affiliations:

María de la Caridad Menéndez-Sainz <sup>a</sup>	MSc, PhD	<a href="mailto:cary@infomed.sld.cu">cary@infomed.sld.cu</a>
Sergio González-García <sup>a</sup>	MSc, PhD	<a href="mailto:sergiogg@infomed.sld.cu">sergiogg@infomed.sld.cu</a>
Alina González-Quevedo <sup>a</sup>	MD, PhD	<a href="mailto:aglez@infomed.sld.cu">aglez@infomed.sld.cu</a>
Marisol Peña-Sánchez <sup>a</sup>	MSc	<a href="mailto:marisol.pena@infomed.sld.cu">marisol.pena@infomed.sld.cu</a>
Rebeca Fernández-Carriera <sup>a</sup>	MSc	<a href="mailto:rebeca@infomed.sld.cu">rebeca@infomed.sld.cu</a>
Anay Cordero-Eiriz <sup>a</sup>	MSc	<a href="mailto:anay@infomed.sld.cu">anay@infomed.sld.cu</a>

<sup>a</sup> Institute of Neurology and Neurosurgery.

Calle 29 N° 114, e/ D y E. Vedado. CP 10400. Havana, Cuba.

### Corresponding author:

Sergio González-García, MSc, PhD.

Email address: [sergiogg@infomed.sld.cu](mailto:sergiogg@infomed.sld.cu)

**Full postal address:** Calle 29 N° 114, e/ D y E. Vedado. CP 10400. Havana, Cuba.

**Telephone:** 537 8345517

## **Abstract.**

*Background.* Lysosomal storage diseases (LSD) are a group of more than 50 genetic disorders and demonstrating deficiency of enzyme activity (EA) should be the first step in its diagnosis. Referral for molecular studies when an LSD is suspected is mainly based in the measurement of the percent relative enzyme activity; nevertheless, the great variability observed in healthy subjects can make the decision unreliable, especially when the patient has some degree of residual activity. *Objectives.* To evaluate the sensitivity and specificity of enzymatic diagnosis in leukocytes and describe normal values of EA in amniocytes and leukocytes. *Design and Methods.* 16 lysosomal enzymes from leukocytes were studied in 151 LSD patients and 869 apparently healthy subjects. Enzyme activities for 13 LSDs were studied in 72 amniocyte cultures at 13 and 18 days culture (12 suspected LSDs and 60 controls). *Results.* The EA for lysosomal enzymes were significantly lower in LSD patients than in controls; the sensitivity and specificity of EA for diagnosis of LSD were mainly above 95% in the majority of the diseases. The normal lysosomal EA in amniocytes was reported; 12 prenatal diagnoses assayed resulted negative for LSD. *Conclusions.* The high sensitivity and specificity of the enzymatic diagnosis of LSDs suggests its utility to identify subjects with the suspicion of LSD. The description of the normal range of 16 lysosomal enzymes in leukocytes and 13 enzymes in amniocytes could be an important source of information for further studies.

## **Introduction.**

Lysosomal storage diseases (LSDs) are a group of more than 50 genetic disorders. Clinical symptoms are caused by the deficiency of specific enzyme(s) function and resultant substrate accumulation in the lysosomes, which leads to impaired cellular function and progressive tissue and organ dysfunction (Yu et al, 2011). LSDs are mainly classified according to the accumulated substrate in sphingolipidosis, glucoproteinosis, mucopolidoses, mucopolysaccharidosis (MPS), and others. Measurements of lysosomal enzyme activities play an important role for the clinical diagnosis of LSDs, because most of them result from a deficiency of one of these enzymes. In a few cases, non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal biogenesis are deficient (Filocamo and Morrone, 2011).

Almost all LSDs show a broad clinical spectrum with respect to the severity of symptoms, age of onset and progression, which is considered to be related with the amount of accumulated

substrates and the different levels of residual enzyme activity (Wenger et al, 2002; Wenger et al, 2003; Wilcox, 2004). The demonstration of enzyme activity deficiency should be the first step in the diagnosis of lysosomal disease (Winchester, 2005), which should be subsequently confirmed by identifying the genetic mutation (Menéndez, 2012).

The definitive enzyme diagnosis of lysosomal storage diseases is demonstrated by the deficiency based on the function of a specific protein, usually enzyme activity, which results in the accumulation or excretion of a particular product storage (Winchester, 2005).

Enzymatic diagnosis can be pre and postnatal, but the main drawback is the wide variability of enzymatic activities in affected patients (or fetuses), possibly due to residual enzyme activity in some cases associated with other factors (Gieselmann, 2005). Additionally, the activities reported for lysosomal enzymes are also very variable in presumably healthy populations, ranging from high specific activities - as is expected in apparently healthy subjects - to lower values, near those reported in patients (Wenger and Louie, 1991; Krasnopolskaya et al, 1993).

Very frequently, the decision on a specific clinical diagnosis for referral to molecular studies is based on the measurement of the percent relative activity (percentage of the specific activity of the patient with respect to that of a control subject assayed in parallel). Nevertheless, in our opinion, the great variability observed in healthy subjects can make the decision unreliable, especially when the patient has some degree of residual activity. The aim of this work was to evaluate the sensitivity and specificity of enzymatic diagnosis of LSDs based on the specific activity of the patients, considering the range of normal values in our laboratory for these enzymes in leukocytes and amniocytes.

## **Materials and Methods.**

One hundred and fifty one patients with enzymatic diagnosis of LSDs and 869 apparently healthy individuals with no family history of presenting any type of LSD (Menéndez, 2012) were included. Seventy-two amniocyte cultures at 13 and 18 days were studied (12-suspected LSDs and 60 controls). The control group was confirmed by healthy pregnant women - with no family history of LSDs and a gestational age between 16-20 weeks as described by Verma et al (1995) and Menéndez et al (2008). Enzyme activity in amniocytes for 13 diseases was measured in 12 pregnant women with gestational age between 16-20 weeks, who requested prenatal diagnosis because of a previous child with LSD.

Sixteen lysosomal enzymes from leukocytes were studied in patients and controls for the quantification of enzyme deficiency by colorimetric and fluorimetric techniques as detailed previously (Menéndez, 2012). Normal specific enzyme activity was calculated for each enzyme in leukocytes and amniocytes. The sixteen lysosomal enzymes were:  $\alpha$ -L-iduronidase (MIM#252800) (EC 3.2.1.76), n-acetylglucosaminidase (MIM#609701) (EC 3.2.1.50), Arylsulfatase B (MIM#611542) (EC 3.1.6.12),  $\beta$ -glucuronidase (MIM#611494) (EC 3.2.1.31),  $\alpha$ -mannosidase (MIM#609458) (EC 3.2.1.24),  $\alpha$ -L-fucosidase (MIM#612280) (EC 3.2.1.51),  $\beta$ -galactosidase (MIM # 611458) (EC 3.2.1.2.3), Hexosaminidase A (MIM#606869) (EC 3.2.1.52), Hexosaminidase A (MIM#606869) yB (MIM#606873) (EC 3.2.1.52), Arylsulfatase A (MIM#607574) (EC 3.1.6.8),  $\beta$ -glucosidase (MIM #606463) (EC 3.2.1.45),  $\alpha$ -galactosidase (MIM #300644) (EC 3.2.1.22),  $\alpha$ -1-4-glucosidase (MIM #606800) (EC 3.2.1.3), Arylsulfatases A,B,C (MIM#607939) (EC 3.1.6), Sphingomyelinase (MIM #257200) (EC 3.1.4.12), Acid Esterase (MIM #278000) (EC 3.1.1.13).

### **Ethical Procedure.**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 2010. Informed consent was obtained from all patients for being included in the study. Proof that informed consent was obtained must be available upon request.

The integrity of the participants was respected; protecting their privacy and the confidentiality of their information, in order to minimize the impact on their physical and mental integrity. Genetic counseling was offered to all pregnant women included in the amniocentesis study, through the Maternal and Child Care Program.

### **Statistical analysis.**

Normality and homogeneity of variance of the enzyme activities were evaluated in normal subjects and patients. Medians of control and patient groups were compared through Mann-Whitney's U test. ROC curve analysis was performed to determine the sensitivity and specificity of enzyme activity for diagnosing the enzyme deficiency. All tests were considered significant at  $p < 0.05$ . Analyses were performed with Statistica v8.0 and SPSS v18.0 programs.

## Results.

### Specific enzyme activity in leukocytes.

In table 1 the enzymatic activity of 16 lysosomal enzymes in patients and controls are shown. All enzyme activities were significantly lower in patients with respect to controls. No patients were diagnosed with the following LSDs: MPS IIIB,  $\beta$ -glucuronidase, Sandhoff's disease and MSD; while only one patient was diagnosed with Fabry's disease and Wolman's disease respectively.

**Table 1. Lysosomal enzyme activities in leukocytes of patients and controls.**

Enzymedeficiency (Disease)	Enzyme activity (nmoles*hour*mg protein).				Mann-W U test Z/p
	Patients	n	Controls	n	
$\alpha$ - L- iduronidase MPS I (MIM #607014)	4.8 (4.5-6.4)	27	8.6 (5.1-13.2)	284	2.26/0.0241
n-acetylglucosaminidase MPS IIIB (MIM #252920)	-	-	32.3 (22.1-70.3)	49	-
Arylsulfatase B MPS VI (MIM#253200)	50.4 (22.2-79.7)	9	185.8 (117.7-325.0)	222	5.08/0.0000
$\beta$ -glucuronidase MPS VII (MIM#253220)	-	-	32.1 (15.4-55.9)	236	-
$\alpha$ -mannosidase $\alpha$ -Mannosidosis (MIM#609458)	11.8 (3.4-33.0)	15	43.5 (25.7-68.3)	246	5.33/0.0000
$\alpha$ -L-fucosidase Fucosidosis (MIM #230000)	3.3 (0.33-9.3)	15	19.6 (12.1-38.7)	272	6.44/0.0000
$\beta$ -galactosidase GM <sub>1</sub> Gangliosidosis (MIM#230500)	3.7 (1.9-10.0)	11	32.7 (17.2-51.4)	244	5.55/0.0000
Hexosaminidase A Tay-Sachs(MIM #272800)	39.1 (5.6-91.4)	8	212.8 (106-358)	117	4.72/0.0000
Hexosaminidases A y B Sandhoff(MIM #268800 )	-	-	116.0 (58.2-208.7)	163	-
Arylsulfatase A MLD (MIM #250100)	9.7 (3.8-21.6)	9	41.6 (24.5-64.4)	254	5.06/0.0000
$\beta$ - glucosidase Gaucher I (MIM # 230800)	0.9 (0.6-6.2)	11	12.1 (6.1-25.1)	150	4.67/0.0000
$\alpha$ -galactosidase Fabry(MIM #301500)	3.3	1	12.6 (4.9-23.0)	67	-
$\alpha$ -1-4-glucosidase Glycogenoses II (MIM #232300)	6.7 (3.9-9.9)	11	13.8 (6.3-22.0)	259	3.64/0.0003
Arylsulfatasas A,B,C MSD (MIM #272200)	-	-	8.4 (5.4-18.6)	145	-

Enzymedeficiency (Disease)	Enzyme activity (nmoles*hour*mg protein).				Mann-W U test Z/p
	Patients	n	Controls	n	
Sphingomyelinase Niemann-Pick A (MIM # 257200) y B (MIM #607616)	22.3 (15.9-24.0)	3	62.1 (39.8-98.3)	135	2.86/0.0042
Acid Esterase Wolman s disease (MIM #27800)	4.5	1	45.5 (23.3-77.4)	20	-
<b>Total determinations</b>		<b>121</b>		<b>2863</b>	

Median (10-90 percentils)

EA: Enzimatic activity (nmoles\*hour\*mg protein).

n: Number of patients and controls.

MLD: metachromatic leukodystrophy

MSD: multiple sulfatase deficiency

Table 2 showsthe sensitivityand specificity, and theproposedcutoff values for 10 lysosomal enzymes. There was practically no overlap between patients and controls, and the sensitivity and specificity for enzymes corresponding to 8 diseases (80%) was very high (> 95%). $\beta$ -glucosidase (Gaucher disease) and  $\alpha$ -1-4-glucosidase (Glycogenoses II) had somewhat lower sensitivity and specificity (82.6% and 88% respectively).

**Table 2.Sensitivityand specificity of specific lysosomalenzyme activities for the diagnosis of LSDs.**

Lysosomal enzyme	n (controls)	Cutoff	Sensitivity	Specificity	p	AUC and 95% Confidence Interval
$\alpha$ - L- iduronidase	284	3.5	99.3%	88.0%	0.000	0.98 (0.96-1.01)
n-acetylglucosaminidase	222	95.6	100%	100%	0.000	1.00 (1.0-1.0)
Arylsulfatase B	246	22.5	100%	88.0%	0.001	0.89 (0.69-1.09)
$\beta$ -glucuronidase	272	13.7	95.7%	100%	0.000	0.99 (0.98-1.01)
$\beta$ -galactosidase	244	14.9	95.7%	100%	0.000	0.99 (0.98-1.01)
Hexosaminidase A	117	96.4	100%	100%	0.000	1.00 (1.0-1.0)
Arylsulfatase A	254	21.9	100%	100%	0.000	1.00 (1.0-1.0)
$\beta$ - glucosidase	150	8.7	82.6%	88.0%	0.000	0.93 (0.83-1.03)
$\alpha$ -1-4-glucosidase	259	8.6	82.6%	88.0%	0.009	0.82 (0.63-1.01)
Sphingomyelinase	135	24.3	98.3%	100%	0.004	0.99 (0.96-1.01)

Median (10-90 percentils)

MLD: metachromatic leukodystrophy

AUC: area under de curve

### Specific enzyme activity in amniocytes

Amniocyte cultures were evaluated for prenatal diagnosis of: MPS I, MPS VI, Fucosidosis, GM1 gangliosidosis Gaucher's disease, TaySachs disease and Niemann Pick A/B. The decision on prenatal LSD diagnosis for the 12 amniocyte cultures from pregnancies with LSD suspicion had been previously established based on relative enzyme activity and published (Menéndez et al, 2008). All relative activities were above 50% and the prenatal diagnosis was considered negative for LSD. Only one prenatal diagnosis (for fucosidosis) displayed a lower relative activity (27.4%), and was referred for molecular diagnosis. Polymerase Chain Reaction analysis in this case revealed a double band (540 and 370 bp), corresponding with a heterozygous for the Q422X mutation. The specific activities for all amniocyte cultures with suspected LSD were well within the normal ranges reported for the respective enzyme, including the fucosidosis heterozygous fetus (10.1 nmoles\*hour\*mg protein). It should be noted that the control amniocyte culture assessed in parallel with this patient displayed a very high specific activity (36.8 nmoles\*hour\*mg protein), outside the normal range presented in Table 3.

The normal range for lysosomal specific enzyme activities in amniocytes at 13 and 18 days culture is shown in table 3.

**Table 3. Lysosomal enzyme activity in normal amniocyte cultures.**

Deficiency (Amniocytes)	Controls (13 days culture)	n	Controls (18 days culture)	n	Mann-Whitney U text Z/p
$\alpha$ -L-iduronidase	0.6 (0.1-2.5)	45	1.2 (0.3-3.9)	29	-2.34/0.0189
Arylsulfatase B	27.3 (22.5-56.3)	15	54.4 (12.8-127.7)	55	-2.71/0.0067
$\beta$ -glucuronidase	1.2 (0.6-5.1)	31	1.5 (0.8-3.4)	24	ns
$\alpha$ -mannosidase	17.8 (1.1-44.9)	37	16.8 (1.7-26.1)	28	ns
$\alpha$ -L-fucosidase	5.8 (0.9-16.1)	46	3.8 (0.5-21.7)	29	ns
Hexosaminidases A y B	40.5 (31.0-69.4)	15	105.8 (24.4-211.9)	14	-2.62/0.0088
Arylsulfatase A	6.9 (4.5-39.3)	14	18.8 (2.7-31.6)	14	ns
$\beta$ -glucosidase	2.7 (0.4-9.3)	47	2.5 (0.4-9.8)	37	ns
$\alpha$ -galactosidase	0.8 (0.3-3.4)	33	1.5 (0.6-6.4)	28	-2.13/0.0326
$\alpha$ -1-4-glucosidase	0.9 (0.5-5.1)	31	1.2 (0.7-3.2)	26	ns
Arylsulfatase A, B y C	0.9 (0.3-2.3)	33	1.7 (0.4-2.8)	40	-2.19/0.0287
$\beta$ -galactosidase	6.7 (0.8-16.6)	43	4.2 (2.8-9.7)	25	ns

Deficiency (Amniocytes)	Controls (13 days culture)	n	Controls (18 days culture)	n	Mann-Whitney U text Z/p
n-acetylneuraminidase	1.2 (0.7-2.7)	10	0.6 (0.3-2.2)	11	ns
<b>Total determinations</b>		<b>400</b>		<b>360</b>	

Median: (10-90 percentil)

MLD: metachromatic leukodystrophy

MSD: multiple sulfatase deficiency

ns: not significant.

## Discussion.

The main result of this work shows a great variability in the specific enzyme activities for all the LSDs assayed in both patient and control groups; nevertheless, patients displayed a highly significant decrease in the activity of lysosomal enzymes compared to controls, confirming the suspected diagnosis of medical specialists. The sensitivity and specificity of enzyme activities for LSD diagnosis was mainly above 95% in the majority of the diseases which were evaluated. Additionally, the normal specific activity of lysosomal enzymes in amniocytes was reported at 13 and 18 days cultures, as well as the results obtained in 12 prenatal diagnoses, all of which resulted negative for the suspected LSD.

Specific enzyme activities- although considerably decreased - were highly variable in patients. All patients assayed in this work had some degree of residual enzymatic activity, in some cases higher or lower than reports in the international literature (Krasnopolskaya et al, 1993). This could be explained due to the high frequency of enzyme polymorphisms reported in genetic studies, as well as other unknown genetic and epigenetic factors, which can influence the phenotype to be developed (Gieselmann, 2005). Other authors have also reported a wide variability in specific activity values (Galjaard et al, 1975; Alkhayat et al, 1998; Hopwood et al, 1990). Additionally, it should be noted that some patients with a substantial residual enzymatic activity could present attenuated forms of the disease.

Despite this residual activity in patients, the sensitivity and specificity of enzymatic activity detection of the 10 studied enzymes was high, in most cases approaching 100%. Only  $\beta$ -glucosidase and  $\alpha$ -1,4-glucosidase showed sensitivity and specificity values between 82-88% and the detection of  $\alpha$ -L-iduronidase reported an 88% specificity.



The normal range of lysosomal specific enzyme activities reported in the literature is very variable (Meikle et al, 2004; Civallero et al, 2006). Our study is not far from this, we found apparently healthy subjects with low specific activity, but which never overlaps with the values of patients. Two main reasons could explain this wide variation in healthy subjects: 1) the methodology of enzymatic diagnosis (method for cell isolation, cell extraction, storage and preservation of enzymes); and 2) genotypic characteristics of the study population, considering the prevalence of the disease, its phenotypic expression and the existence of pseudodeficiencies (de Gasperiet al, 2000; Li et al, 2004). Families with pseudodeficiencies have been reported in MLD and fucosidoses (Gort, 2000).

Emory University has a panel for lysosomal specific enzyme activities employing diagnostic methodology similar to ours (fluorimetric methods in leukocytes), which reported ranges of lysosomal enzyme activity in healthy subjects. Despite the technological similarities, only the enzyme activity of arylsulfatase A,  $\alpha$ -L-iduronidase and  $\alpha$ -D-mannosidase in healthy individuals were analogous between our group and Emory University (<http://geneticslab.emory.edu>). On the other hand, the specific enzyme activity values for  $\alpha$ -galactosidase,  $\alpha$ -L-fucosidase, and  $\beta$ -galactosidase obtained by us in healthy subjects were 2-4 times lower than those reported by this University; while the range of values for  $\beta$ -glucosidase, hexosaminidase A and arylsulfatase enzyme activity in our study displayed a lower variability than those reported by Emory University (<http://geneticslab.emory.edu>). These differences could be explained by the high level of African and European admixture in Cuba, with varying proportions, which are dissimilar to Native American populations (Mao et al, 2008). In addition, the African admixture in our population is higher than in US cities (Parra et al, 1998; Cintado et al, 2009). Another factor, which could be involved, is the possibility of having some pseudodeficients in the healthy population.

During the study period of 20 years there were no differences in the variability of enzyme activities in normal subjects with time; that is, the variability was the same in samples assayed at the beginning, middle or the end of the 20 year period. This supports the view that variability is not subject to a specific time or to any methodological or equipment feature, but must be mainly related to the reasons discussed above.

Lysosomal substrate storage may begin early during embryonic development, and the clinical presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease (Filocamo and Morrone, 2011). Therefore when an affected fetus is suspected, it is important

to detect the enzyme deficiency in the prenatal stage. Prenatal diagnosis is performed on the most appropriate samples, which include fresh or cultured chorionic villus sampling or cultured amniotic fluid. The fluorimetric enzyme test from chorionic villus is recommended, as it can be done 3-4 weeks earlier than amniocentesis, which is medically and ethically more favorable. Nevertheless, the choice of obtaining the sample by amniocentesis or chorionic villus depends on the gestational age at which the patient was seen for the first time (Aboul and Fateen, 2004).

The advent of prenatal diagnosis has radically altered the management of pregnancy and perinatal outcomes. Many of the molecular, genetic, functional and structural conditions affecting the offspring can be detected now in utero, and sometimes even treated before birth. For this reason, many couples seek counseling before pregnancy, especially when there has been a previously affected child or when the parents are known or suspected carriers of a disease with autosomal recessive transmission (Casagrandi et al, 2005; Menéndez et al, 2008).

The complete absence of lysosomal enzyme activity generally confirms diagnosis. Conversely, the presence of normal lysosomal enzyme activity cannot exclude a specific diagnosis if it is accompanied by suggestive clinical symptoms and/or the abnormal presence of metabolites in the urine and/or storage in peripheral smear and/or tissue biopsy (Filocamo and Morrone, 2011). However, reduced lysosomal enzyme activity could define a specific diagnosis when the specific enzymatic activity of the patient is below the lower limit of the normal range reported in healthy subjects or below the cut off value obtained from the ROC curve for that enzyme, as shown by the high sensitivity and specificity obtained, in spite of the great variability observed in controls. Thus, the report of lysosomal specific enzyme activity is more accurate than the report of percentage activity, because the last depends on the value of the control employed.

The high sensitivity and specificity of the enzymatic diagnosis of LSDs described in this article demonstrate its utility to identify subjects with the suspicion of lysosomal disease. The description of the normal range of 16 lysosomal enzymes in leukocytes and 13 enzymes in cultured amniotic cells is an important source of information for further studies that could be reported in this issue.

## References

- [1] Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides—An overview. *J Oleo Sci* 2011; 60: 537–44.
- [2] Filocamo M, Morrone A. Lysosomal storage disorders: Molecular basis and laboratory testing. *Hum Genomics* 2011;5:156–69.
- [3] Wenger DA, Coppola S, Liu SL. Lysosomal storage disorders: diagnostic dilemmas and prospects for therapy. *Genet Med* 2002;4:412-19.
- [4] Wenger DA, Coppola S, Liu SL. Insights into the diagnosis and treatment of lysosomal storage diseases. *Arch Neurol* 2003;60:322-28.
- [5] Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. *J Pediatr* 2004;144:S3-14.
- [6] Winchester B. Lysosomal metabolism of glycoproteins. *Glycobiology* 2005;15:1R-15R.
- [7] Menéndez MC. Diagnóstico enzimático de las enfermedades de almacenamiento lisosomal: experiencia de 20 años. Tesis en opción al título de Doctor en Ciencias de la Salud. Universidad de Ciencias Médicas de La Habana. 2012. Available from: [http://tesis.repo.sld.cu/view/year/2012.html#group\\_M](http://tesis.repo.sld.cu/view/year/2012.html#group_M).
- [8] Gieselmann V. What can cell biology tell us about heterogeneity in lysosomal storage diseases? *Acta Paediatr* 2005;94:80–6.
- [9] Wenger DA, Louie E. Pseudodeficiencies of arylsulfatase A and galactocerebrosidase activities. *Dev Neurosci* 1991;13:216-21.
- [10] Krasnopolskaya KD, Mirenburg TV, Aronovich EL, Lebedeva TV, Odinkova ON, Demina NA, et al. Diagnosis and Prevention of Lysosomal Storage Diseases in Russia. *J Inher Metab Dis* 1993;16:994-1002.
- [11] Verma R and Babu A. *Human chromosomes: Principles and techniques*. 2da ed. McGraw-Hill. 1995:72-127.
- [12] Menéndez C, González S, Peña M, Menéndez LA, Quiñones O, Diepa N, et al. Diagnóstico prenatal enzimático de enfermedades lisosomales en Cuba. *Rev Ecuat Neurol* 2008;17:1-3.
- [13] Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. Cited 2010 Jul(21); Available from: <http://www.wma.net/es/>
- [14] Galjaard H, Hoogeveen A, de Wit-Verbeek HA, Reuser AJ, Ho MW, Robinson D. Genetic heterogeneity in GM1 gangliosidosis. *Nature* 1975;257:60-2.

- [15] Alkhatat AH, Kraemer SA, Leipprandt JR, Macek M, Kleijer WJ, Friderici KH. Human beta-mannosidase cDNA characterization and first identification of a mutation associated with human beta-mannosidosis. *Hum Mol Genet* 1988;7:75-83.
- [16] Hopwood JJ, Morris CP. The mucopolysaccharidoses: Diagnosis, molecular genetics and treatment. *Mol Biol Med* 1990;7:381-404.
- [17] Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. *Pediatrics* 2004;114:909-16.
- [18] Civallero G, Michelin K, de Mari J, Viapiana M, Burin M, Coelho JC, et al. Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected lysosomal storage diseases. *Clin Chem* 2006;372:98-102.
- [19] deGasperi R, Raghavan SS, Sosa MG, Kolodny EH, Carrier C, Rubenstein P, et al. Measurements from normal umbilical cord blood of four enzymatic activities:  $\alpha$ -L-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy), arylsulfatase A (metachromatic leukodystrophy), arylsulfatase B (Maroteaux-Lamy). *Bone Marrow Transpl* 2000;25:541-44.
- [20] Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, et al. Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn Screening. *Clin Chem* 2004; 50:1785-96.
- [21] Gort L. Anàlisi molecular de la mucopolisacaridosi I, la mucopolisacaridosi II i la leucodistrofia metacromàtica en els pacients espanyols. Utilitat diagnòstica i correlació genotip-fenotip. Tesis Doctoral. Instituto de Bioquímica Clínica. 2000. Barcelona. España.
- [22] Lysosomal Storage Disease: Panel Enzyme Activity (13 Enzymes), Leukocytes. Emory Genetics Laboratory. Available from: <http://geneticslab.emory.edu>
- [23] Mao X, Bigham AW, Mei R, Gutierrez G, Weiss KM, Brutsaert TD, et al. A genome wide admixture mapping panel for Hispanic/Latino populations. *Am J Hum Genet* 2007;80:1171-78.
- [24] Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al. Estimating African American admixture proportions by use of population-specific alleles. *Am J Hum Genet* 1998;63:1839-51.
- [25] Cintado A, Companioni O, Nazabal M, Camacho H, Ferrer A, De Cossio ME, et al. Admixture estimates for the population of Havana City. *Annals of Human Biology* 2009;36:350-60.

- [26] Aboul A, Fateen E. Prenatal diagnosis of Mucopolysaccharidoses: The first Egyptian experience. BratislLekListy 2004;105:291-340.
- [27] Casagrandi CD, Zaldivar T, Nodarse RA, Carballo CS. Algunos aspectos éticos del diagnóstico prenatal, la medicina y terapia fetales. Rev Cubana ObstetGinecol2005;31:0-0.